 |
市場調査レポート
世界の合弁事業・事業提携の動向：製薬企業、バイオテクノロジー企業、診断企業の場合Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 |
||||||
| 発行 | Current Partnering, a division of Wildwood Ventures Limited | 商品コード | 315594 | ||||
| 出版日 | ページ情報 | 英文 439 Pages 納期: 即日から翌営業日 |
|||||
| 価格 |
|
||||||
| 世界の合弁事業・事業提携の動向：製薬企業、バイオテクノロジー企業、診断企業の場合 Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 | ||
| 出版日: 2017年09月01日 | ページ情報: 英文 439 Pages |
|
当レポートでは、世界の最大手バイオテクノロジー（ライフサイエンス）企業における合弁事業（ジョイントベンチャー）取引や事業提携（パートナーシップ）取引の動向について分析し、合弁事業締結の理由・契機や方法、目的の達成度、契約・取引の条件、関係企業の一覧とプロファイル（コンタクト情報など）といった情報をお届けいたします。
※ このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture partnering agreements entered into by the worlds leading healthcare companies.
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive understanding and unprecedented access to the joint venture deals and agreements entered into by the worlds leading life science companies.
This report provides details of the latest joint venture agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of joint venture agreements from 2010.
There is an increasing willingness for parties to enter joint venture deals; such deals enable both parties to benefit from the upside of a big product win, whereas traditional licensing deals forfeit upside for near term upfront, milestone and royalty payments.
Joint venture partnering allow the parties to securitize value and reduce risk, but keep a part of the potential upside should the product reach the market. Event if the licensor does not commercialize the project they can either sell those rights to the licensee partner or another partner for an amount higher than would have been achieved at an earlier stage licensing deal.
Another reason for joint venture deals is the joint origin of a project. Drug development projects often require various scientific and technological novelties that stem from different companies. If both companies contributed to the origination of the project, then both have from the beginning a stake in the project.
The report provides a detailed understanding and analysis of how and why companies enter joint venture deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all joint venture deals announced since 2010 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual joint venture contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of joint venture dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in joint venture as well as a discussion on the merits of the type of deal.
Chapter 3 provides an overview of the structure of joint venture deals. The chapter includes numerous case studies to enable understanding of joint venture deals.
Chapter 4 provides a review of the leading Joint venture deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
Chapter 5 provides a comprehensive listing of the top 50 most active Joint venture dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 6 provides a comprehensive and detailed review of Joint venture deals organized by company A-Z, therapy, technology and industry type signed and announced since 2010 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the Joint venture deal.
The appendices to the report includes a comprehensive listing of all Joint venture deals announced since 2010. Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.
The report also includes numerous table and figures that illustrate the trends and activities in Joint venture dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about Joint venture alliances.
Key benefits
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 includes:
In Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 available deals and contracts are listed by:
The Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 report provides comprehensive access to available contract documents for joint venture deals. Analyzing actual contract agreements allows assessment of the following:
Global Joint Venture Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010-2017 provides the reader with the following key benefits:
